{
  "thread": {
    "uuid": "40cd5e3e93b7e31d1a579e12111888459d535014",
    "url": "http://sc.stock.cnfol.com/gushizhibo/20250731/31510267.shtml",
    "site_full": "sc.stock.cnfol.com",
    "site": "cnfol.com",
    "site_section": "http://sc.stock.cnfol.com/gushizhibo/",
    "site_categories": [
      "financial_news",
      "finance",
      "stocks"
    ],
    "section_title": "股市直播 _ 市场 _ 中金在线",
    "site_title": null,
    "title": "港股异动 | 康方生物(09926)涨近5%再创新高 依沃西联合方案治疗IO耐药NSCLC三期临床完成首例给药_股市直播_市场_中金在线",
    "title_full": "港股异动 | 康方生物(09926)涨近5%再创新高 依沃西联合方案治疗IO耐药NSCLC三期临床完成首例给药_股市直播_市场_中金在线",
    "published": "2025-07-31T06:47:00.000+03:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 10644,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "40cd5e3e93b7e31d1a579e12111888459d535014",
  "url": "http://sc.stock.cnfol.com/gushizhibo/20250731/31510267.shtml",
  "ord_in_thread": 0,
  "author": null,
  "published": "2025-07-31T06:47:00.000+03:00",
  "title": "港股异动 | 康方生物(09926)涨近5%再创新高 依沃西联合方案治疗IO耐药NSCLC三期临床完成首例给药_股市直播_市场_中金在线",
  "text": "智通财经APP获悉，康方生物(09926)早盘涨近5%，高见160.4港元，再创历史新高。截至发稿，涨3.86%，报158.7港元，成交额9.5亿港元。\n　　消息面上，康方生物宣布，公司自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西(商品名：依达方?)联合多西他赛，用于治疗经PD-1/L1 抑制剂和含铂化疗治疗失败的局部晚期或转移性非小细胞肺癌的注册性III期临床研究(AK112-305/HARMONi-8A)，已完成首例患者给药。\n　　值得注意的是，这是依沃西在肺癌领域开展的第7项III期研究(其中3项为国际多中心注册临床)。作为全球首创的PD-1/VEGF双抗，依沃西已在NSCLC领域实现了核心适应症的全面覆盖，完成多线治疗的布局，有望重塑全球晚期NSCLC的整体治疗格局。同时，依沃西也作为公司“IO+ADC”2.0 战略的核心 IO 双抗基石药物，已经针对肿瘤免疫核心适应症一线治疗开展了一系列 III 期临床和 II 期临床。\n　　 　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Economy, Business and Finance",
    "Science and Technology",
    "Human Interest"
  ],
  "topics": [
    "Economy, Business and Finance->healthcare industry",
    "Economy, Business and Finance->business information",
    "Economy, Business and Finance->financial service",
    "Science and Technology->medical research",
    "Science and Technology->biomedical science",
    "Science and Technology->scientific publication",
    "Human Interest->record and achievement"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-07-31T07:58:56.552+03:00",
  "updated": "2025-07-31T08:05:04.000+03:00"
}